Creative Medical taps CRO Syneos to run Type 1 diabetes cell therapy study

Biotech Creative Medical Technology has tapped Syneos Health to run a phase 1/2 randomized trial of its cell therapy for the potential treatment of Type 1 diabetes.

Creative Medical’s candidate CELZ-201 recently received the green light from the FDA to enter a trial on its safety and efficacy, which is expected to begin by the end of the month.

The cell therapy is touted as taking a new approach to leveraging the self-renewal abilities and low antigenicity of cells taken from perinatal tissue, the Phoenix-based company said in a March 7 press release. Financial details of the partnership weren’t disclosed.

“The commencement of this first-in-country clinical trial is a milestone event for Creative Medical Technology Holdings and a reflection of our commitment to developing novel therapies with the potential to address areas of high unmet medical need,” Creative's CEO Timothy Warbington said in the release.

Last month, Syneos launched a decentralized clinical trial site network with the aim of driving "digital health technology solutions." Initially launching in the U.S. and Canada, the network will cover therapeutic areas as varied as internal and general medicine, family practice, neurology, endocrinology, pediatrics and psychiatry, to name a few.